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Dendritic cells (DCs) are uniquely potent antigen presenting cells that acquire microbial
products and prime adaptive immune responses against pathogens. Furthermore, DCs
also play a key role in induction and maintenance of tolerance. Although numerous studies
have assessed the diverse functions of DCs, many unanswered questions remain regarding
the molecular mechanisms that DCs use to achieve immunoregulation. While not widely
regarded as a significant provider ofT-cell growth factors, DCs have previously been identi-
fied as a potential source of IL-2 cytokine. Recent research indicates that microbes are the
most effective stimuli to trigger IL-2 production in DCs by activating the calcineurin/NFAT
signaling pathway. Herein we describe recent insights into the production and function of
IL-2 cytokine and IL-2 receptor in DCs early after stimulation through pattern recognition
receptors. These findings clarify how DCs fine-tune effector and regulatory responses by
modulating IL-2 production in both tolerance and immunity.
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INTRODUCTION
The emergence of multicellular organisms during evolution has
been accompanied by the concomitant development of the innate
immune system, which serves to protect the host from pathogen
colonization. Co-evolution of multicellular systems and their asso-
ciated microbiomes over millions of years has produced a sophisti-
cated host receptor repertoire and signaling networks that respond
to specific perturbations in homeostasis. This ability to sense the
environment is best demonstrated by dendritic cells (DCs), which
have developed the capacity to respond to ligation of specific
pathogen recognition receptors (PRRs) in order to trigger adaptive
immune responses. Among the many different responses induced
by PRR ligation in DCs, we have found that specific agonists can
stimulate translocation of the transcription factor “nuclear fac-
tor of activated T-cells” (NFAT) to the DC nucleus both in vitro
and in vivo, resulting in the activation and regulation of gene
expression (Granucci et al., 2001; Zanoni et al., 2009). Interest-
ingly, one of the gene products regulated by NFAT in DCs is
the interleukin (IL)-2 (Granucci et al., 2001), which is particu-
larly crucial to the functioning of the immune system in both
immune homeostasis and immunity (Malek, 2008). In the late
1970s, Kendall A. Smith and Steven Gillis described IL-2 cytokine
as a T-cell growth factor produced by T lymphocytes (Smith,
1988). In the subsequent 40 years, the wider role played by IL-2
in regulating the adaptive immune response has been fully rec-
ognized. Although previous studies of this cytokine have focused
primarily on T-cells, new findings have highlighted that IL-2 is
also produced by other cell types and in various different settings.
For these reasons, IL-2 can be defined as a pleiotropic cytokine
with different functions extending from driving T-cell prolifer-
ation, supporting the activation of natural killer (NK) cells to
the induction of pro-apoptotic gene transcription (Malek, 2008).
Indeed, the many diverse functions of IL-2 are well demonstrated
by the spontaneous development of autoimmune and inflamma-
tory bowel diseases in mice that are deficient for IL-2 or the IL-2
receptor (IL-2R; O’Shea et al., 2002). Notably, adoptive transfer of
IL-2-sufficient T-cells or administration of IL-2 cytokine can sig-
nificantly ameliorate disease in these animals (Malek and Castro,
2010).
In the myeloid immune compartment, IL-2 gene transcription
is inducible in DCs but not in macrophages or in other phagocytic
cells (Granucci et al., 2001). The initial finding that IL-2 produc-
tion by DCs is a major outcome of PRR ligation raised the question
of whether it could contribute to adaptive immune responses. In
this review we will summarize the current knowledge about the
functional role of IL-2 as an innate cytokine.
INDUCTION OF IL-2 TRANSCRIPTION IN DCs
Kinetic transcriptional profiling has shown that developmentally
synchronized DCs grown in medium containing GM-CSF pro-
duce IL-2 within 4–6 h of stimulation with alive Gram-negative
Escherichia coli bacteria. Interestingly, the kinetic of the IL-2
mRNA expression and of IL-2 protein production were similar.
In contrast, macrophages are not able to produce IL-2 under these
conditions (Granucci et al., 2001). Thus, the narrow window of
transcription and secretion of IL-2 is unique to DCs.
Because of the crucial role played by DCs in initiating and reg-
ulating immune responses, it is key to clarify the kinetics of IL-2
production as well as the stimuli which elicit this cytokine and the
signaling machinery which support IL-2-secretion by DCs. Indeed,
DCs are well established, as critical mediators of antimicrobial
immunity, and it would appear that microbial products are the
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most potent stimuli for IL-2 production by myeloid DCs. In this
regard, Granucci et al. (2003) showed that LPS, peptidoglycan, and
CpG ligands for Toll-like receptors (TLRs) were able to trigger vari-
able levels of IL-2 release. In contrast, pro-inflammatory cytokines
including TNF-α, IFN-α, and IL-1β failed to stimulate IL-2 pro-
duction by DCs. Interestingly, myeloid DCs were also shown to
produce very high amounts of IL-2 in response to zymosan or fol-
lowing challenge with live yeast Saccharomyces cerevisiae (Granucci
et al., 2003). Immature DCs exhibit marked phagocytic activity,
but phagocytosis of inert particles per se does not constitute a
trigger for IL-2 by DCs (Granucci et al., 2003). In contrast, block-
ade of DC phagocytic activity by treatment with Latrunculin B
inhibits antigen uptake and IL-2 production by these cells (Rogers
et al., 2005) but does not impair the production of IL-12p40 and
IL-10 in response to zymosan. This study also investigated the
intracellular signaling pathway that leads to IL-2 production in
DCs, showing that murine bone marrow-derived and splenic DCs
grown in GM-CSF-enriched medium were able to produce large
amounts of IL-2 cytokine via Syk kinase signaling and receptor
dectin-1 binding. Dectin-1, also known as CLEC7A, is a C-type
lectin receptor expressed in myeloid cells and specifically binds
1–3 β-glucan on the cell wall of fungi (Sancho and Reis e Sousa,
2012). The main feature of this PRR is that it expresses a hemITAM
motif, which recruits Src kinase and Syk kinase (Figure 1). Syk
then recruits CARD9 to the membrane and activates the canonical
NF-κB signaling pathway through the CARD9/Blc10/Malt-1 com-
plex. Dectin-1 can also activate the non-canonical NF-κB pathway
through RelB. The pro-inflammatory response triggered by NF-
κB signaling, with subsequent increases in IL-23p19, TNF-α, and
IL-6 production, is counterbalanced by a regulatory response char-
acterized by the production of IL-2 and IL-10 (Sancho and Reis
e Sousa, 2012). In this context, IL-2 is likely to be transcribed
through the NFAT transcriptional gene program (Granucci et al.,
2001; Goodridge et al., 2007). The binding of 1–3 β-glucan to
dectin-1 induces the dephosphorylation of Src kinases through
the surface molecule CD45. Once activated, Src kinases phospho-
rylate the ITAM motif of dectin-1, which then forms a docking
site for Syk. Phospholipase C (PLC)γ-2 is subsequently activated
by Syk to stimulate increases in intracellular Ca2+ flux, culmi-
nating in the translocation of NFAT into the nucleus (Figure 1).
Thus, uptake of fungal particles via dectin-1 is reminiscent of
the synapse formed between T-cells and antigen presenting cells
(Goodridge et al., 2011). This is due to the exclusion of CD45
from the phagocytic synapse when particles are recruited to the
phagocytic cup, which facilitates prolonged dectin-1 signaling via
Syk and subsequent NFAT translocation.
The molecules involved in NFAT signaling were primarily
described in T-cells about 20 years ago. In contrast, NFAT expres-
sion in myeloid cells has been identified only recently (Muller and
Rao, 2010). Furthermore we have shown that NFAT controls the
development and homeostasis of the myeloid compartment (Fric
et al., 2012). In resting DCs, NFAT remains phosphorylated in
the cytoplasm, and the translocation of NFAT between cytoplasm
and nuclei is tightly regulated by a number of protein kinases
and phosphatases. The NFAT family of transcription factors com-
prises five members; NFAT1 (NFATc2 or NFATp), NFAT2 (NFATc
or NFATc1), NFAT3 (NFATc4), NFAT4 (NFATx or NFATc3), and
FIGURE 1 | IL-2 release by DCs stimulation of PRRs triggers the
calcineurin/NFAT pathway via PLC-γ2 and intracellular Ca2+ flux. NFAT
dephosphorylation by calcineurin leads to IL-2 transcription and release,
which is increased in response to CD40/CD40L interactions. CD25 (IL-2Rα)
can capture IL-2 release in the synaptic cleft on the surface of DCs for
presentation in trans to adjacent T-cells.
NFAT5 (TonEBP; Muller and Rao, 2010; Buxade et al., 2012). In
2009, it was reported that smooth LPS could trigger Ca2+ flux
through CD14, independently of TLR4 ligation. LPS signaling
through this pathway drives NFAT1 translocation and regulates
various transcripts that control DC survival and apoptosis (Zanoni
et al., 2009; Figure 1). LPS-induced Ca2+mobilization was depen-
dent on PLCγ-2 and required CD14 localization in lipid rafts.
More recently, CD14 has also been shown to play an essential role
for the internalization of TLR4, which is endocytosed in response
to LPS stimulation via Syk and PLCγ-2 (Zanoni et al., 2011).
Re-phosphorylation of NFAT in the nucleus is also regulated
by several kinases; CK1, GSK3, and DYRK. The phosphorylation
status of NFAT in the cytoplasm of DCs can be further modu-
lated by Leucine-rich repeat kinase 2 (also known as dardarin),
a recently described negative regulator of NFAT1 signaling in
myeloid cells (Liu et al., 2011). Calcineurin is a key calcium-
dependent phosphatase, which mediates NFAT signaling (Jain
et al., 1993; McCaffrey et al., 1993). Calcium flux stimulates
calcineurin to dephosphorylate NFAT, thereby promoting NFAT
translocation into nuclei. In T-cells, activation of this cascade
induces gene transcription and leukocyte activation, thereby dri-
ving the production of NFAT-dependent cytokines including IL-2,
IL-4, GM-CSF, and TNF-α (Rao et al., 1997).
More recently, mice that conditionally lack NFAT or cal-
cineurin in myeloid cells were also studied and a key role for
calcineurin/NFAT signaling in the innate immune compartment
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has been demonstrated (Greenblatt et al., 2010). Indeed the stim-
ulation of myeloid cells with live fungi or with fungal cell wall
extracts such as curdlan or zymosan results in the activation
of a number of genes regulated through NFAT. In macrophages
exposed to zymosan, transcription targets include genes which
encode IL-10, IL-12, cyclooxygenase-2 (Cox-2), and members of
the early growth response (Egr) family of transcription factors,
Egr2 and Egr3 (Goodridge et al., 2007). In bone marrow-derived
DCs, zymosan was similarly found to trigger IL-2, IL-10, and IL-
12p70 production in an NFAT-dependent manner. Importantly,
the levels of IL-2 released in response to β-glucan particles were
comparable to the known levels of IL-2 normally detected in T-cell
cultures in response to lectins (Slack et al., 2007). The intracellu-
lar levels were detected in response to zymosan particles at the
same time points as in response to LPS (Rogers et al., 2005).
Since zymosan also activates TLR2 and Myd88 signaling, the IL-
2 production detected by these assays was found to be partially
dependent on Myd88 expression. Intriguingly, IL-2 was seemingly
co-produced with IL-10 in a Myd88-independent manner (Rogers
et al., 2005). Zymosan-stimulated cytokine production was also
found to depend at least in part on TLR2 expression (Goodridge
et al., 2007). In DCs, ERK activation is required for maximal pro-
duction of IL-2, which is Myd88-independent but does require Syk
(Slack et al., 2007). These data clearly show that the Syk-dependent
pattern recognition is extremely important for TLR-independent
anti-fungal immune responses.
IMMUNO-REGULATORY ROLE OF DC-PRODUCED IL-2
The role played by DC-derived IL-2 in immune responses has
been difficult to interpret since many other innate and adaptive
cell types can produce large quantities of this cytokine in vivo
(Boyman and Sprent, 2012). Indirect evidence of a contribution
from DC-derived IL-2 to host protection comes from the observa-
tion that DCs infected with murine cytomegalovirus (MCMV)
lose the ability to produce IL-2 in response to LPS (Andrews
et al., 2001). The finding that MCMV inhibits IL-2 production
implies that DC production of this cytokine is detrimental to
the pathogen and may therefore contribute to protective immu-
nity. It is possible then that one strategy employed by MCMV
to escape immune surveillance is by decreasing DC potential for
T-cell priming (Andrews et al., 2001). In addition, it is known
that IL-2 supports T-cell proliferation, drives the production of
cytokines including IFN-γ and TNF-α, and regulates the homeo-
static survival of lymphoid lineage cells. Recent investigations of
how regulatory T-cells (Tregs) are induced and maintained have
now demonstrated how IL-2 contributes to both tolerance and
immunity (Cheng et al., 2011).
Several roles have been proposed for IL-2 cytokine produced
by DCs. One hypothesis is that DC-derived IL-2 can enhance NK
cell functions, and accordingly, cross talk between NK cells and
IL-2-producing DCs increases IFN-γ production by the NK cells
(Zanoni et al., 2005). DCs appear then to provide important stim-
uli for the priming and cytotoxic function of NK cells (Granucci
et al., 2008). Notably it has been observed that IL-2-deficient
DCs are impaired in their ability to stimulate the proliferation
of allogeneic T-cells (Granucci et al., 2001). In mixed lympho-
cyte reactions, DCs primed with bacteria were used to stimulate
allo-reactive CD4+ and CD8+ T-cells. These experiments con-
firmed that IL-2-deficient DCs were poor antigen presenting cells
compared with wild-type DCs. Similarly, when T-cell proliferation
was tested by flow cytometry, very few cycling T-cells were detected
in co-cultures stimulated by IL-2-deficient DCs (Granucci et al.,
2001). These data clearly indicate that IL-2 produced by DCs
significantly affects T-cell activation in mice. In humans, the pro-
duction of IL-2 by activated human DCs has been shown (Feau
et al., 2005) and more recently the activation of human T-cells
by DC-produced IL-2 was also revealed using an in vitro IL-2-
secretion assay (Wuest et al., 2011). IL-2 also regulates important
aspects of Treg biology including the thymic development and sup-
pressive function of these cells (Cheng et al., 2011). This has led
to the evaluation of potential therapeutic strategies that employ
IL-2 cytokine to expand Tregs (Yamazaki et al., 2007). Guiducci
et al. (2005) reported that DCs impaired in IL-2 production fail to
expand Tregs in vivo, suggesting an important role for DC-derived
IL-2 in the regulation of Treg biology. It has also been reported
that IL-2 produced by DCs enhances CD40/CD40L interaction
thus promoting Treg expansion (Guiducci et al., 2005). When DCs
are loaded with cognate antigens and are co-cultured with T-cells
IL-2-secretion may be detected in the immune synapse (Wuest
et al., 2011). In the synaptic cleft, IL-2 released by DCs has been
found to bind in an autocrine manner to the α-subunit of the
IL-2R (CD25). This subunit is expressed on the surface of DCs
and presents IL-2 in trans to the other two signaling chains of the
IL-2R on T-cells (Figure 1). The IL-2-related cytokine IL-15 can
signal in a similar fashion (Stonier and Schluns, 2010), and it is
possible that DC secretion of IL-2 in the synaptic cleft may pro-
vide an efficient and previously unexpected “signal 3” for T-cells,
including T effector and Tregs. Other than transpresentation, it
might be also possible that DC IL-2R is important for autocrine
maturation (Mnasria et al., 2008) and eventually may function as
decoy receptor. It remains to be determined how the IL-2-secretion
that follows PRR ligation in DCs can lead to either the activation
of effectors or regulatory T-cell functions.
INNATE IL-2 AS A POTENTIAL NEW TARGET IN CLINICAL
STUDIES
We have shown that early IL-2 production by DCs in response
to PRR ligation exerts important functions in both innate and
adaptive leukocytes. The potential key role for the early produced
IL-2 in innate responses requires tight regulation at the transcrip-
tional level to control the absolute levels of this cytokine in the
microenvironment and in the immune synapse. Immune home-
ostasis may depend in part on the ongoing production of IL-2,
which exerts a critical influence on the differentiation and function
of Tregs (Malek, 2008). Indeed, in a recent observational cohort
study, daily sub-cutaneous administration of low-dose IL-2 was
found to be associated with Treg expansion and a reduction in
clinical manifestations of graft-versus-host disease (Koreth et al.,
2011). More importantly, drugs such as cyclosporin A (CsA) and
tacrolimus (FK506; Flanagan et al., 1991; McCaffrey et al., 1993)
potently block the calcineurin/NFAT signaling pathway and are
widely used to prevent transplant rejection and autoimmune dis-
eases, but these drugs also increase risk of infection. Intriguingly,
treatment with CsA can also increase susceptibility to Candida
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albicans infection in mice that lack conventional lymphocytes
(Greenblatt et al., 2010) suggesting that the drug must also act
on non-lymphoid cell types.
The newly uncovered functions of IL-2 might therefore explain
how drugs that modify the calcineurin/NFAT pathway impact on
immune homeostasis and induce side effects in treated patients.
Indeed, the ability of DCs to produce IL-2 and other NFAT regu-
lated proteins is impaired upon such treatment (Goodridge et al.,
2007). The quantitative and qualitative effects of DC-derived IL-2
thus constitute a new level of regulation of the immune response
after microbial encounter and open new paths for identification
of new therapeutic targets.
EARLY IL-2 PRODUCTION IN MYELOID DCs IN DIFFERENT
TISSUES
• In the skin there are dermal DCs, epidermal DCs, and Langer-
hans cells (LCs) with very different functional capabilities
(Kaplan, 2010a,b). Murine LCs stimulated with LPS in vitro and
analyzed by flow cytometry display IL-2 production by intracel-
lular staining. IL-2 production was abrogated by CsA treatment
(Granucci et al., 2003).
• In the spleen, both CD8+ and CD8− subsets of CD11c+ DCs
were found to produce IL-2 following injection with LPS,
zymosan, or bacteria (Granucci et al., 2003).
• Genomic profiling of DCs and macrophages has confirmed
that IL-2 transcription following PRR activation is an exclusive
feature of DCs (Granucci et al., 2001).
• Human myeloid DCs produce IL-2 in response to LPS via a
mechanism that depends on CD40L and IL-15 (Feau et al.,
2005).
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